European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- -

The heart of Monograph 0478 lies in its mandated quality control tests. These tests are designed to guarantee that every batch of tablets meets predefined criteria for identity, purity, and performance.

1. Appearance and Identification The monograph requires a visual description of the tablets (color, shape, markings). More critically, it mandates a specific identification test for the active substance(s), typically using High-Performance Liquid Chromatography (HPLC) or Infrared (IR) spectroscopy. This prevents mix-ups and ensures the correct drug is present.

2. Uniformity of Dosage Units This is arguably the most critical safety and efficacy test. It ensures that each tablet in a batch contains the active substance within a narrow range (typically 85–115% of the label claim). The test is performed according to General Chapter 2.9.40, using either content uniformity (individual assay of 10 tablets) or mass variation (weighing tablets for potent drugs). Failure here indicates poor manufacturing mixing or compression, leading to underdosing (ineffectiveness) or overdosing (toxicity).

3. Dissolution (or Disintegration) For solid dosage forms, the active substance must be released and absorbed to be effective. The monograph gives priority to the Dissolution Test (2.9.3) , which measures the percentage of drug released into a specified medium over time (e.g., 80% in 30 minutes). For rapidly dissolving tablets of highly soluble drugs, a Disintegration Test (2.9.1) may be substituted, where tablets are placed in a basket-rack assembly in water at 37°C and must disintegrate within a specified time (e.g., 15 minutes for uncoated tablets). For enteric-coated tablets, the monograph specifies two stages: resistance to disintegration in acidic medium (simulating stomach), followed by disintegration in neutral buffer (simulating intestine). European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

4. Uniformity of Mass A simpler, practical test for non-potent drugs where the active substance comprises a large proportion of the tablet weight. Twenty tablets are weighed individually; the average mass is calculated, and no more than two tablets deviate from the average by more than 5% (or 7.5% for larger tablets).

5. Additional Tests for Specific Types

For a pharmaceutical manufacturer, Monograph 0478 is more than a technical document. It is the legal gateway to sell tablets in Europe. If your QC report claims "Conforms to Ph. Eur. 0478," you are legally declaring that every batch released meets the standards for: The heart of Monograph 0478 lies in its

Failing to adhere to the 2023 revisions of 0478 is a Class 1 deficiency in any EMA inspection, leading to potential import bans, product recalls, or manufacturing authorization suspension.

All tablets must comply with the following tests unless otherwise stated in an individual monograph.

These are designed to release the active substance(s) at a defined time or over an extended period. Failing to adhere to the 2023 revisions of

One of the most critical sections of 0478 deals with Uniformity of Dosage Units. In a manufacturing run of millions of pills, how do you ensure every single one has the exact same amount of medicine?

The monograph references strict testing methods to ensure that the variance between tablets is statistically insignificant. This is where the "mass variation" test meets the "content uniformity" test. If a tablet contains a tiny amount of potent API (like a hormone or an opioid), weighing the tablet isn't enough; chemists must assay the content of individual units. 0478 dictates when to use which method, ensuring that a patient never receives a "super-potent" or "sub-potent" dose.

Monograph 0478 is the cornerstone of Quality Control (QC) and Quality Assurance (QA) for oral solid dosage forms in Europe.

Tablets are solid preparations each containing a single dose of one or more active substances. They are obtained by compressing uniform volumes of particles or by another suitable manufacturing process (e.g., compaction, granulation followed by compression).

Based on FDA and EMA warning letters citing Ph. Eur. 0478 (or equivalent national requirements), here are the top 5 failures: